Progression of a-synuclein inclusion pathology may occur through cycles of release and uptake of a-synuclein aggregates, which induce additional intracellular a-synuclein inclusion pathology. This process may explain (i) the presence of a-synuclein inclusion pathology in grafted cells in human brains, and (ii) the slowly progressive nature of most human a-synucleinopathies. It also provides a rationale for therapeutic targeting of extracellular aggregates to limit pathology spread. We investigated the cellular mechanisms underlying intraneuronal a-synuclein aggregation following exposure to exogenous preformed a-synuclein amyloid fibrils. Exogenous asynuclein fibrils efficiently attached to cell membranes and were subsequently internalized and degraded within the endosomal/lysosomal system. However, internalized a-synuclein amyloid fibrils can apparently overwhelm the endosomal/ lysosomal machinery leading to the induction of intraneuronal a-synuclein inclusions comprised of endogenous a-synuclein. Furthermore, the efficiency of inclusion formation was relatively low in these studies compared to studies using primary neuronal-glial cultures over-expressing a-synuclein. Our study indicates that under physiologic conditions, endosomal/lysosomal function acts as an endogenous barrier to the induction of a-synuclein inclusion pathology, but when compromised, it may lower the threshold for pathology induction/transmission.
a-synuclein (aS) neuronal inclusions, also known as Lewy bodies and Lewy neurites can present in a spectrum of neurodegenerative disorders, termed synucleinopathies, such as Parkinson's disease (Goedert 2001; Waxman and Giasson 2008a; Goedert et al. 2013) . Neuropathology studies have shown that the presentation of aS pathology can appear to follow a temporal neuroanatomical sequence associated with disease severity (Braak et al. 2006a ) and that aS pathology may even start in the peripheral nervous system (Wakabayashi et al. 1988; Braak et al. 2006b ). Indeed, the appearance of Lewy bodies in fetal dopaminergic neurons that were transplanted in the striatum of PD patients (Kordower et al. 2008; Li et al. 2008 Li et al. , 2010 supports the notion that aS pathology may be transmitted between neurons. In addition, several studies have demonstrated that aS can be imported or exported across cell membranes (Ahn et al. 2006; Lee et al. 2008a; Desplats et al. 2009; Emmanouilidou et al. 2010 ) consistent with the observed intercellular exchange of aS in cellular animal graft studies (Desplats et al. 2009; Kordower et al. 2011; Reyes et al. 2013) . Indeed, application of exogenous aS amyloid or biological samples containing aggregated aS can induce in mice the progressive spread of intra-neuronal aS inclusion pathology (Luk et al. 2012a,b; Mougenot et al. 2012; Masuda-Suzukake et al. 2013; Sacino et al. 2013a Sacino et al. , 2014a Watts et al. 2013; Betemps et al. 2014) . Despite the growing body of data supporting a prion-like mechanism for pathology induction, not all of the results obtained from these studies are consistent with pathology induction solely via conformational templating. Other additional disease-modifying factors such as direct cellular toxicity, proteostasis impairments, or endosomal dysfunction need to be considered as additional mechanisms (Brundin et al. 2008; Sacino and Giasson 2012; Golde et al. 2013; Uchihara and Giasson 2015) .
Several non-mutually exclusive mechanisms including release by exocytosis Liu et al. 2009) or cell death, uptake by various endocytosis mechanisms (Sung et al. 2001; Ahn et al. 2006; Lee et al. 2008a Lee et al. , 2010 , release/uptake of exosomes (Emmanouilidou et al. 2010; Danzer et al. 2012) , and even conceivable nanotube tunneling (Gousset et al. 2009 ) could be involved in the intercellular transmission of aS aggregates. A previous study reported that the simple addition of extracellular aS fibrils to primary neurons could induce the formation of intracellular aS inclusions in primary neuronal cultures (VolpicelliDaley et al. 2011 ), but we demonstrated that some of the critical data could be confounded by the lack of specificity of a key reagent, antibody pSer129/81A, which also recognizes phosphorylated neurofilament low-molecular mass subunit (NFL) (Sacino et al. 2014c) .
Using recombinant adeno-associated virus-mediated aS over-expression in mouse primary neuronal-glial cultures, we previously showed that exposure to exogenous aS amyloid seeds efficiently induced intracellular aS inclusion pathology in cells over-expressing aS, and that this inclusion formation occurred in a fashion that was consistent with conformational templating (Sacino et al. 2013b) . However, in contrast to another published report (Volpicelli-Daley et al. 2011 ), we did not detect inclusion pathology formation in the absence of aS over-expression in neuronal-glial cultures. Here, we revisited studies in non-aS over-expressing primary neuronal-glial cultures. Using a pSer129 aS antibody that has demonstrated a high degree of specificity, we show that exogenous aS amyloid fibrils can induce the intraneuronal aggregation of endogenous aS in na€ ıve primary cultures under defined conditions. However, this process shows limited efficiency with only a subset of neurons developing inclusion pathology following exposure to aS fibrils. We further establish the dual role of endocytosis and endosomal/ lysosomal function in fibril uptake that can lead to pathology induction or endolysosomal degradation of aS representing a significant physiological barrier to pathology spread.
Methods

Antibodies
See Table 1 for complete list of aS antibodies. Anti-phospho-Ser129 aS rabbit monoclonal antibodies EP1536Y and MJF-R13 (8-8) were obtained from Abcam (Cambridge, MA, USA). A rabbit polyclonal antibody against NFL was generously provided by Dr Gerry Shaw (Encor Biotechnology Inc. Gainesville, FL) and an anti-NFL rabbit monoclonal antibody C28E10 was purchased from Cell Signaling Technology, Danvers, MA, USA. Mouse anti-NFL antibody NR4 was obtained from Sigma-Aldrich (St Louis, MO, USA). Mouse anti-actin (clone C4) monoclonal antibody reacts with all forms of vertebrate actin (Millipore, Billerica, MA, USA). A polyclonal rabbit anti-glial fibrillary acidic protein antibody was purchased from Dako (Carpinteria, CA, USA). Anti-vimentin (C20) rabbit antibody was from Santa Cruz Biotechnology Inc (Dallas, TX, USA). Neuronal-specific mouse monoclonal anti-bIII tubulin antibody TuJ-1 was purchased from Fisher Scientific (Hanover Park, IL, USA), while neuronal-specific rabbit anti-bIII tubulin antibody (T2200) was obtained from SigmaAldrich. Rabbit anti-LC3A monoclonal antibody D50G8 was obtained from Cell Signaling Technology.
Reagents
Dynasore was purchased from Sigma-Aldrich and bafilomycin A was from EMD Millipore.
Primary neuronal-glial cultures
All procedures were performed according to the NIH Guide for the Care and Use of Experimental Animals and were approved by the University of Florida Institutional Animal Care and Use Committee. Antibody pSer129/81A only reacts with aS when phosphorylated at Ser129, but it also cross-reacts with neurofilament low-molecular mass subunit (NFL) phosphorylated at Ser473 (Sacino et al. 2014c) .
SNCA (aS) null mice (Abeliovich et al. 2000) were obtained from The Jackson Laboratory (Bar Harbor, MA, USA). Primary cultures (embryonic) were prepared from E16-E18 C3HBL/6 mouse brains (Harlan Labs, Indianapolis, IN). Cerebral cortices were dissected from E16-E18 mouse brains and were dissociated in 2 mg/mL papain (Worthington, Lakewood, NJ) and 50 lg/mL DNAase I (Sigma, St Louis, MO, USA) in sterile Hank's Balanced Salt Solution (Life Technologies, Carlsbad, CA, USA) at 37°C for 20 min. They were washed three times in sterile Hank's balanced salt solution to inactivate the papain and switched to 1% fetal bovine serum (FBS; HyClone, Logan, UT, USA) in Neurobasal-A growth media (Gibco, Rockville, MD, USA), which includes 1% GlutaMax Supplement (Life Technologies), B-27 supplement, 100 units/mL penicillin, and 100 lg/mL streptomycin. The tissue mixture was triturated three times using a 5 mL pipette followed by a Pasteur pipette, and strained through a 70 lm nylon cell strainer. The cell mixture was then centrifuged at 1300 g for 3 min, and resuspended in fresh Neurobasal-A media. They were then plated on Nunc Lab-Tek II CC2 chamber slides or onto poly-D-lysine-coated cell culture dishes (Life Technologies) at around 100 000-200 000 cells/cm 2 . Cells were maintained in the Neurobasal-A growth media without FBS at 37°C in a humidified 5% CO 2 chamber. These cultures are comprised of approximately 20% neurons and 80% glial cells based on the percentage of total cells stained for bIII-tubulin (neuronal marker) or vimentin (glial cell marker).
CHO cells
Chinese hamster ovary (CHO) cells were cultured in Dulbecco's modified Eagle medium high glucose (4.5 gm/L) supplemented with 10% FBS, 100 U/mL penicillin, 100 U/mL streptomycin, and 2 mM L-glutamine.
Preparation of recombinant aS fibrils
Recombinant 21-140 human and full-length human or mouse wildtype aS proteins were expressed and purified as described previously Greenbaum et al. 2005; Giasson 2010, 2011) . For amyloid assembly, aS proteins (5 mg/mL) were incubated in sterile phosphate-buffered saline (PBS; Life Technologies) at 37°C with continuous shaking at 1050 rpm (Thermomixer R; Eppendorf, Westbury, NY, USA) and fibril formation was monitored by turbidity and K114 fluorometry (Waxman and Giasson 2010) . Fibrils were diluted to 2 mg/mL in sterile PBS and sonicated for 1 h, which results in fragmentation into smaller fibrils of varying lengths (Waxman and Giasson 2010; Sacino et al. 2014c) (Figure S1 ). Cultures were treated with 10 or 20 lg/mL of aS fibril mix at 6 DIV and maintained thereafter as indicated for each experiment.
Negative staining electron microscopy aS filaments were absorbed to 300-mesh carbon-coated copper grids and stained with 1% uranyl acetate as described previously (Giasson et al. 1999) . Images were captured with a JEOL 1010 transmission electron microscope (Peabody, MA, USA) mounted with a Hamamatsu digital camera (Bridgewater, MA, USA) using AMT software (Danvers, MA, USA).
Biochemical cellular fractionation
For total cell lysates, cells were washed with PBS and directly lysed in 2% sodium dodecyl sulfate (SDS), 50 mM Tris pH 6.8 and heated to 100°C for 10 min. Protein concentrations were determined by bicinchoninic acid assay (Pierce, Rockford, IL, USA) using bovine serum albumin as standard.
For trypsin degradation of extracellular aS fibrils, cells were washed with PBS and treated with 0.25% trypsin for 10 min. Trypsin was inactivated with 20% FBS/PBS. Cells were washed with PBS and directly lysed in 2% SDS, 50 mM Tris pH 6.8, and heated to 100°C for 10 min.
For biochemical fraction, cultures were washed with PBS and lysed in CSK buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 20 mM NaF, 2 mM EDTA, 1% Triton X-100) with protease inhibitors and placed on ice for 10 min. Lysates were then centrifuged at 100 000 g for 30 min at 4°C. Supernatants were saved as the Triton-soluble fraction, and the pellet was washed with the CSK buffer and recentrifuged. The pellet was then resuspended in 2% SDS, sonicated and heated to 100°C for 10 min. 2% SDS was added to the Triton-soluble fraction that was heated to 100°C.
Western blotting analysis
Equal amounts of cellular protein lysates or volumes of cell culture media were resolved by SDS-polyacrylamide gel electrophoresis on 13% polyacrylamide gels, followed by electrophoretic transfer onto nitrocellulose membranes. Membranes were blocked in Tris-buffered saline (TBS) containing 5% dry milk, and incubated overnight with primary antibodies in TBS/5% dry milk, except pSer129/81A and D37A6 antibodies that were probed overnight in TBS/5% bovine serum albumin. A total anti-actin antibody (clone C4) (Millipore) was used as a loading control. Probing with primary antibodies was followed by goat anti-mouse conjugated horseradish peroxidase (Amersham Biosciences, Piscataway, NJ, USA) or goat anti-rabbit horseradish peroxidase (Cell Signaling Technology). Protein bands were detected using chemiluminescent reagent (NEN, Boston, MA, USA) and a FluorChem Imager (Protein Simple, San Jose, CA, USA).
Immunofluorescence microscopy analysis
For double immunofluorescence analysis, cells were washed with PBS and fixed with 4% paraformaldehyde/PBS. Following PBS washes, cells were blocked with 5% FBS/PBS/0.1% Triton X-100 for 30 min. Cultures were incubated in primary antibodies followed by Alexa-fluor 488 and 594 conjugated secondary antibodies (Invitrogen, Carlsbad, CA, USA). Nuclei were counter-stained with Neuronal-glial cultures were maintained for 6 days and (b) recombinant full-length human aS fibrils (10 lg/mL) or (c) recombinant 21-140 human aS fibrils (10 lg/mL) were added and cultured for an additional 3 days. Cells were extensively washed with phosphate buffered saline, fixed, and immunostained with anti-amino-terminal aS specific antibody Syn 506 (red), anti-human aS specific antibody Syn 204 (red), or anti-human aS specific antibody Syn 211 (red) and anti-glial fibrillary acidic protein (GFAP) antibody (green). Cultures were stained with GFAP to visualize astrocytes in the culture. Merged images are shown. Higher magnification merged images are shown on the far right. Bar = 100 and 250 lm for the higher magnification images on the right. 4',6-diamidino-2-phenylindole (Invitrogen), and coverslips were mounted using Fluoromount-G (Southern Biotech, Birmingham, AL, USA). For standard immunofluorescence, images were captured with a Olympus BX51 fluorescence microscope mounted with a DP71 digital camera (Olympus, Center Valley, PA, USA).
For confocal immunofluorescence analyses of the association of exogenous human aS fibrils with the surface plasma membrane, cells were extensively washed with PBS, fixed with 4% paraformaldehyde, washed and immunostained with cholera toxin subunit B conjugated to Alexa 647 (Invitrogen) without cell permeabilization. Cholera toxin subunit B binds to the cell surface ganglioside GM1; therefore, it reliably identifies surface membrane. Again without permeabilization, cells were incubated with antihuman aS antibody Syn 204 followed by anti-mouse antibody conjugated to Alexa-fluor 488. Images were captured using an inverted Nikon TE2000-UCI laser scanning confocal microscope (Nikon, Melville, NY, USA) with 609 1.49NA Plan-Apo objective (Nikon) and Nikon NIS-Elements software.
Results
Exogenous aS fibrils extensively associate with cell membrane Addition of preformed aS fibrils to primary neuronal-glial cultures that over-express aS results in the robust induction of intracellular amyloidogenic aS inclusions; however, in non-aS over-expressing cultures this was not observed (Sacino et al. 2013b ). We conducted numerous additional studies to evaluate aggregation of endogenous aS in na€ ıve neuronal-glial cultures following exposure to exogenous aS fibrils. Using anti-aS antibodies that recognized epitopes that Fig. 2 Analysis of endogenous murine aS and exogenous human aS fibrils in primary neuronal-glial cultures. Neuronal-glial cultures were maintained for 6 days and untreated (À) or treated (+) with recombinant full-length human aS fibrils (10 lg/mL) and cultured for an additional for 4 days. Cultures are shown in triplicate. The cultures were extensively rinsed with phosphate-buffered saline and fractionated with CSK buffer as described in 'Material and Methods' to generate Triton-soluble (S) fractions and Triton-insoluble (P) fractions. Cell lysates were resolved onto 13%-polyacrylamide gels and analyzed by immunoblotting with (a) antibody SNL-1 that reacts equally with murine and human aS, (b) antibody D37A6 that specifically reactions with murine aS, or antibodies (c) Syn 211and (d) Syn 204 that specifically reacts with human aS. The asterisk (*) indicates a major breakdown product of exogenous aS that forms when associated with cells. A separate lane on the left on each blot is shown to demonstrate the migration pattern of intact exogenous aS fibrils that was used to treat the cultures. The mobilities of the molecular mass markers are shown on the right. are present only in the exogenously added human aS fibrils, we found that exogenous aS aggregates efficiently adhere to cell membranes ( Fig. 1; Figure S2 ). For example, staining with amino-terminal specific aS antibody Syn 506 or carboxy-terminal specific human aS antibodies Syn 204 or Syn 211 in cultures treated with full-length human fibrillar aS result in the widespread staining of cell even after extensive washing with PBS prior to fixation (Fig. 1b;  Figure S2 ). This close association between exogenous aS aggregates and the outside of cell membranes was confirmed by staining without permeabilizing cells with detergent and confocal microscopy ( Figure S3 ). In comparison, the staining of exogenous aS aggregates is not observed with antibody Syn 506 if the fibrils are comprised of amino-terminal truncated 21-140 human aS (Fig. 1c) indicating that the staining is largely because of exogenously added aS fibrils adhering to cells.
Biochemical fractionation studies of neuronal-glial cultures treated with exogenous full-length human aS fibrils showed that the exogenous fibrils attaching to cells were predominantly fractionated in the Triton-insoluble fraction (Fig. 2 ). When detected with antibodies such as SNL1 that reacts with both human and mouse aS, there appears to be the generation of Triton-insoluble aS species (Fig. 2a) , but when a mouse aS-specific antibody is used, it is clear the vast majority of endogenous mouse aS was found in the Triton-soluble fraction (Fig. 2b) . We also observed an aS cleavage product (indicated by asterisks) derived from the exogenous human aS fibrils as this band was detected by the anti-aS human antibody Syn 204 (Fig. 2d) . This protein fragment results from cleavage between amino acid residues 110 and 120, as it was detected by antibodies Syn 204 and SNL1, but not Syn 211 (Fig. 2) .
To evaluate whether fibrillar aS bound to cells remained predominantly extracellular, fibrillar aS exposed to primary neuronal-glial cells were treated with trypsin. Trypsin treatment almost completely eliminated intact human aS fibrils and the cleaved fragment associated with the cells, but also generated a new band migrating slightly below 15 kDa (Fig. 3a) . Trypsin treatment may have eliminated the human aS fibrils associated with the cells by either direct degradation of human aS or by allowing it to be released from cell surface proteins that it is tethered to. Nevertheless, these studies show that the majority of the human aS fibrils associated with cells are extracellular. The residual trypsin-resistant human aS fragments could represent either internalized aS or trypsin-resistant species; however, in the absence of cells, trypsin is capable of completely degrading human aS fibrils (Fig. 3b) . Furthermore, we find that incubation of cells with soluble, nonaggregated, human aS results in minimal association with the cell membrane, or if it does bind cells, it is very rapidly cleared (Fig. 3a) .
Cell-associated exogenous aS fibrils are degraded in neuronal-glial cultures To further investigate how exogenous human aS fibril is processed following attachment to cells and the generation of the aS cleavage products, we performed time course studies (Fig. 4a) . The total aS in the cell culture media was relatively stable up to 96 h following addition to the cultures (Fig. 4a) . Exogenous aS rapidly associated with cells (within 10 min of application), reached maximal levels by 24 h, and then decreased over a 48-h period. Notably, as the levels of fulllength exogenous aS associated with the cells decreased, there was a concomitant increase in the cleaved C-terminal fragment in the cells (Fig. 4a) .
The amount of exogenous aS associated with the neuronglial cells in the constant presence of exogenous fibrillar aS represents a combination of aS that is de novo attaching to the cells, already bound to the cell surface, and that has been internalized. To monitor the specific turnover of only the aS that is already associated with the cells, after allowing exogenous aS to bind to the cells for 8 h, the media was replaced with new media that did not contain exogenous aS (Fig. 4b) . Both full-length and the C-terminal truncated aS product of fibrillar aS initially present were progressively degraded with a half-life estimated at 3-5 days. We found no evidence that exogenous aS fibrils associated with the cells were secreted or released back in the cell culture media ( Figure S4 ).
Endosomal/lysosomal degradation of exogenous aS fibrils To determine if aS fibrils can absorb to and be degraded by non-neuronal/glial cells, similar studies were performed with CHO cells. Human aS fibrils readily adhered to CHO cells, but CHO cells displayed even more robust degradation of aS fibrils (Fig. 5a ). To assess whether the protease activity involved in degrading aS was secreted, human aS fibrils were incubated in na€ ıve or conditioned media, and no significant degradation was observed (Fig. 5b) . These data suggested that a cellular protease activity was involved in the degradation of exogenous aS fibrils. To characterize this cellular activity, we first treated cells with, ammonium chloride or chloroquine, compounds that inhibit lysosomal function by neutralizing the acidic organelles. Treatment with either agent significantly blocked the degradation of fibrillar aS associated with CHO cells (Fig. 5c ). To further characterize this cellular process, we treated cells with bafilomycin A, a drug that not only prevents lysosomal function by inhibiting vacuolar proton ATPase but also blocks fusion between autophagosomes and lysosome (Bowman et al. 1988; Yamamoto et al. 1998) . To confirm that chloroquine and bafilomycin A were effective at the concentrations used, we assessed the levels of LC3A-I and the phosphatidylethanolamine modified form of this protein LC3A-II ( Figure S5 ), established markers of autophagosome/ lysosome activities (Tanida et al. 2008) . In addition, we treated cells with dynasore, an inhibitor of dynamin GTPase activity which is required for coated vesicle endocytosis (Macia et al. 2006) . Both bafilomycin A and dynasore reduced the degradation of exogenous fibrillar aS (Fig. 5d) .
To determine if a similar mechanism was involved in the degradation of fibrillar aS by neuronal-glial cultured cells, Fig. 4 Degradation of exogenous human aS fibrils in primary neuronal-glial cultures. (a) Neuronal-glial cultures were maintained for 6 days and treated with recombinant full-length human aS fibrils (10 lg/mL) for the times indicated in minutes (min) or hours (h). The cell culture media (TC media) or total cell lysates, harvested after extensive washes with phosphate-buffered saline (PBS), were analyzed by immunoblotting with anti-human aS antibody Syn 204. (b) Neuronal-glial cultures were maintained for 6 days and untreated (À) or treated (+) with recombinant full-length human aS fibrils (10 lg/mL) for 4 days. The cell culture media was replaced with fresh media without exogenous aS. At the times indicated, cells were extensively washed with PBS and total cell lysates were analyzed by immunoblotting with antibodies Syn 211 and SNL-1 to determine the turnover of exogenous aS attached to cells. The asterisk (*) indicates the major breakdown products of exogenous aS that forms when associated with cells. The immunoblot was also probed with an actin antibody for a loading control. The mobilities of the molecular mass markers are shown on the right.
we assessed the effect of lysosomal inhibitors in these cells. Treatment of cells with ammonium chloride or chloroquine resulted in the stabilization of exogenous human aS fibrils attached to cells (Fig. 5e) . These results suggest that lysosomal impairment could lead to the accumulation of exogenous aS fibrils within vesicles. We further investigated this possibility using dual immunofluorescence assays. Primary neuronal-glial cultures with treated with aS fibrils and chloroquine for 2 days; staining with pSer129/81A antibody staining showed robust accumulation of intracellular phosphorylated aS staining that was not seen in cultures treated with aS fibrils or chloroquine alone or in na€ ıve cultures (Fig. 6d-arrow heads) . This labeling was clearly distinct from labeling of neuronal process by pSer129/81A that is because of the cross-reactivity with phosphorylated NFL (Fig. 6a-arrows) . This data indicated that lysosomal inhibition may result in the intracellular accumulation of internalized human aS fibrils that become phosphorylated, as the same findings were obtained from cultures from aS null mice indicating that these pSer129/81A (a) CHO cells were untreated (À) or treated (+) with recombinant full-length human aS fibrils (10 lg/mL) for the times indicated. Cells were extensively washed with phosphate-buffered saline (PBS) and total cell lysates were analyzed by immunoblotting. The asterisk (*) indicates the major breakdown products of exogenous aS that forms when associated with cells. (b) Recombinant full-length human aS fibrils (10 lg/mL) were not incubated (started) or incubated for 3 days in PBS, CHO cells culture media (M), or CHO cells conditioned media (from confluent cells; CM) and were analyzed by immunoblotting. (c) CHO cells were untreated (À) or treated (+) with recombinant full-length human aS fibrils (10 lg/mL) for the times indicated. As indicated, some cells were also concurrently challenged with 100 lM chloroquine or 25 mM ammonium chloride. Cells were extensively washed with PBS and total cell lysates were analyzed by immunoblotting. (d) CHO cells were untreated (À) or treated (+) with recombinant full-length human aS fibrils (10 lg/mL) for the times indicated. As indicated, some cells were also concurrently challenged with 1 nM bafilomycin A or 60 lM dynasore. Cells were extensively washed with PBS and total cell lysates were analyzed by immunoblotting. (e) Neuronal-glial cultures were maintained for 6 days and treated with recombinant full-length human aS fibrils (10 lg/mL) for 2 days in the presence of 100 lM chloroquine or 25 mM ammonium chloride as indicated. The treatment with chloroquine or ammonium chloride resulted in a greater than two fold accumulation of cellular-associated aS fibrils. Cells were extensively washed with PBS and total cell lysates analyzed by immunoblotting with antibody Syn 204 as well as with an actin antibody for a loading control. The mobilities of the molecular mass markers are shown on the right.
immuno-positive structures were not because of accumulation of endogenous mouse aS (Fig. 6e) . To further demonstrate that it was the exogenous human aS fibrils that were internalized and accumulating after becoming phosphorylated, we show that that pSer129/81A-positive puncta did not appear in primary neuronal-glial cultures from aS null mice were treated with Ser129Ala aS fibrils in the presence of chloroquine (Fig. 6f ). Cultures were double Neuronal-glial cultures from wild-type (WT) mice were maintained for 6 days and either left untreated (a), treated with recombinant 21-140 human aS fibrils (10 lg/mL) for 2 days (b), treated with 100 lM chloroquine for 2 days (c), or treated with both 21-140 human aS fibrils (10 lg/mL) and 100 lM chloroquine for 2 days (d). Neuronal-glial cultures from aS null mice were maintained for 6 days and treated with both 21-140 human aS fibrils (10 lg/mL) and 100 lM chloroquine for 2 days (e). Neuronal-glial cultures from aS null mice were maintained for 6 days and treated with both Ser129Ala 21-140 human aS fibrils (10 lg/mL) and 100 lM chloroquine for 2 days (f). Merged images are shown. Higher magnification merged images are shown on the far right. Arrowheads indicate the intracellular accumulation of phosphorylated human aS fibrils puncta. Arrows depict labeling of neurofilament low-molecular mass subunit (NFL)-positive neuronal neurites because of cross-reactivity of antibody pSer129/81A aS with phosphorylated NFL (Sacino et al. 2014c) . Bar = 100 and 250 lm for the higher magnification images on the right.
labeled with vimentin, a non-neuronal cell marker, to demonstrate that intracellular accumulation of phosphorylated exogenous human aS fibrils occurred in various cell types and not just neurons. Additionally, we also show that intracellular accumulation of phosphorylated exogenous human aS fibrils in the presence of chloroquine can occur in neurons ( Figure S6 ).
Induction of intraneuronal aS aggregation with exogenous aS fibrils
We speculated that if exogenous aS fibrils are targeted to the endolysosomal pathway following internalization, then saturating the cells with excess aS fibrils can overwhelm the cells' intrinsic degradation machinery leading to additional pathologies, including recruitment of endogenous aS. In many studies where we had treated cultures with 10 lg/mL 21-140 human, full-length human, or mouse aS fibrils for 2-10 days, we failed to detect any reproducible and significant biochemical or immune-staining evidence for endogenous aS induction formation in our neuronal-glial cultures. In contrast, in studies where we increased the concentration of exogenous aS fibrils to 20 lg/mL, we were able to reproducibly observe the formation of pSer129/81A-stained aggregates that did not co-localize with NFL suggesting that these are indeed intracellular aS aggregates induced by exogenous aS fibrils ( Fig. 7a and b, arrows) . Hyperphosphorylation of aS at Ser129 is one of the best indicators of pathological aS inclusion formation (Fujiwara et al. 2002; Anderson et al. 2006; Giasson 2008b, 2010) , but many anti-pSer129 aS antibodies lack specificity; in particular, the pSer129/81A antibody can strongly cross-react with NFL phosphorylated at Ser129 (Sacino et al. 2014c) . Therefore, as a further proof that the intracellular aggregates were composed of endogenous aS, we used the aminoterminal aS antibody Syn 506, an epitope absent in the exogenous 21-140 human aS fibrils. Indeed, we observed Syn506-positive intracellular aggregates (Fig. 7d) that were not present in untreated cultures (Fig. 7c) , although the overall amount was less than detected with pSer129/81A on the same cultures (Fig. 7a) . Thus, pSer129 immunoreactivity was clearly a more robust marker of aggregate formation, but staining with the pSer129/81A antibody did not always provide clear-cut data. In some control cultures that were maintained for 8-12 days, the staining from phospho-NFL cross-reactivity associated with neuronal degeneration often resembled aS aggregates. To try to identify other pSer129 aS antibodies that would not have the issue of cross-reactivity with NFL, we recently screened several anti-pSer129 aS antibodies for their ability to detect aggregated phosphorylated aS without crossreaction with phosphorylated NFL (Uchihara and Giasson 2015) . We found that antibodies pSer129/EP1536Y and pSer129/MJF-R13 (8-8) could react with aS phosphorylated at Ser129 without cross-reacting with phosphorylated NFL (Uchihara and Giasson 2015) . However, we found that the pSer129/MJF-R13 (8-8) antibody strongly labeled neurons even in na€ ıve cultures from aS null mice; indeed, in some cultures the staining of neuritic processes had a beaded pattern resembling frank aS aggregates in seeded cultures ( Figure S7 ). This finding is consistent with the pSer129/MJF-R13 (8-8) antibody reacting with non-aS proteins as observed by immunoblotting using mouse brain lysates (Uchihara and Giasson 2015) . Conversely, the pSer129/ EP1536Y antibody demonstrated very low non-specific staining except for some weak nuclear staining.
Using the pSer129/EP1536Y antibody that is not confounded with cross-reactivity to phosphorylated NFL, we then demonstrated that the addition of exogenous aS fibrils at 20 lg/mL resulted in progressively increasing (2-10 days) hyperphosphorylated aS aggregates in neuronalglial cultures (Fig. 8) . These aggregates could be similarly induced with the addition of exogenous fibrils comprised of 21-140 human aS (Fig. 8b-d) , full-length mouse aS (Fig. 8e, h ), or full-length human aS (Fig. 8f) and was not induced in cultures from aS null mice (Fig. 8g) . To further investigate the formation of aS intracellular aggregates by exogenous aS fibrils in these cultures, we performed biochemical fractionation followed by immunoblot analysis (Fig. 9 ). The treatment with exogenous fibrils over 10 days resulted in the accumulation of Triton X-100 insoluble aS aggregates, which were also resistant to SDS and heating as they remained at the top of the resolving gels. These aS aggregates were detected with pSer129 aS antibodies 81A, MJF-R13 (8-8) and EP1536Y and antimouse aS specific antibody D37A6 indicating that they are comprised of endogenous pSer129 phosphorylated aS. These aggregated forms of exogenous aS were also resistant to urea/SDS treatment (Fig. 9b) . Interestingly, Fig. 8 Induction of endogenous aS aggregates with exogenous aS fibrils in primary neuronal-glial cultures. Primary neuronal-glial cultures from WT mice (a-f, h) or aS null mice (g) were cultured for 6 days and either (a) maintained without other treatment for 4 days, (b) treated with 21-140 human aS fibrils (20 lg/mL) for 2 days, (c) treated with 21-140 human aS fibrils (20 lg/mL) for 4 days, (d) treated with 21-140 human aS fibrils (20 lg/mL) for 10 days, (e) treated with full-length mouse aS fibrils (20 lg/mL) for 4 days, or (f) treated with full-length human aS fibrils (20 lg/mL) for 4 days. (g) Primary neuronal-glial cultures from aS null mice or (h) WT mice were cultured for 6 days and treated with full-length mouse aS fibrils (20 lg/mL) for 10 days. Double immunofluorescence analysis with antibodies pSer129/EP1536Y (red) and specific neuronal marker bIII-tubulin (green) was performed. Merged images are shown. Higher magnification merged images are shown on the far right. Arrows depict induced pSer129/EP1536Y labeled aS aggregates. Bar = 100 and 250 lm for the higher magnification images on the right.
probing with a human aS-specific antibody, Syn 204 revealed that the residual exogenous human aS migrated as a protein smear indicating that it was being extensively modified over time.
Discussion
The progressive formation of aS inclusion pathology in patients with neurodegenerative diseases may occur, at least in part, through recurring cycles of release and uptake of aS aggregates which is capable of inducing additional intracellular aS inclusion pathology. Here, we have focused on elucidating the cellular mechanisms that regulate the uptake of aS fibrils and subsequent induction of aS inclusion pathology. We find that in the absence of cellular overexpression of aS, the recruitment of endogenous aS into inclusions in primary neuronal-glial cultures is relatively inefficient and requires the application of relatively high concentrations of exogenous fibrils. Mechanistically, we show (i) that exogenous aS aggregates rapidly bind the extracellular plasma membranes of both neurons and glia, a finding consistent with other studies using different methods (Reyes et al. 2013) , and (ii) that the bound fibrils are internalized and degraded within the endosomal/lysosomal system. Internalization involves dynamin-mediated endocytosis, but micropinocytosis may also contribute to this process (Doherty and McMahon 2009; Lim and Gleeson 2011; Holmes et al. 2013; Mulcahy et al. 2014) . Interestingly, the major mechanisms involved in the cytoplasmic degradation of endogenous aS, macroautophagy, and chaperone-mediated autophagy, also require lysosome activity (Paxinou et al. 2001; Webb et al. 2003; Cuervo et al. 2004; Lee et al. 2004; Vogiatzi et al. 2008; Mak et al. 2010) . Therefore, these findings suggest that the major mechanisms for the degradation of both exogenous aS fibrils and endogenous cytoplasmic aS converge on lysosomal activity.
These and other recent data provide an important framework to help understand cell-to-cell spread of aS inclusion pathology. This framework is highly consistent with hypothetical mechanistic constraints for amyloid formation through a nucleation and concentration-dependent conformational templating mechanism and the normal cellular proteostatic machinery that is designed to clear protein aggregates from the cell. Indeed, efficiency of seeding is enhanced by (i) increased levels of aS over-expression, which likely promotes rapid fibril elongation in the presence of an exogenous aS seed, and (ii) increased concentrations of fibrils applied to the cells, which then would be expected to increase the likelihood for nucleation of amyloid formation. In the latter case, increasing amounts of fibrils applied to the cells might not only result in more uptake of the fibrils, but also less efficient degradation as there is a precedence for amyloid fibrils within the lysosomes to perturb lysosomal function (Tofaris 2012; Dehay et al. 2013) . Further, our data would suggest that under more physiologic settings (e.g. endogenous levels of aS expression and low levels of extracellular aS aggregates), cellular homeostatic mechanisms are able to handle the potential proteotoxic stressors. Efficient degradation of exogenous aS fibrils following uptake within the endosomal/lysosomal system likely limits the ability of these fibrils to nucleate new inclusions, and even if occasional nucleation events occurred, it is possible that the proteostatic mechanism could rapidly clear these from the cell. As there is both (i) genetic evidence that compromised lysosomal function may be associated with risk for PD (Tofaris 2012; Dehay et al. 2013) , and (ii) evidence that aging may result in impaired lysosomal and autophagic functions (Damme et al. 2015; Wong and Holzbaur 2015) , our current data thus provide tantalizing links between cell-to-cell spread of pathological aS and risk factors for PD.
Although our previous data from aS over-expressing primary neuronal-glial cultures is consistent with a prion-like conformational templating mechanism, as seeding by A53T or E46K aS fibrils produces different inclusion morphologies (Sacino et al. 2013b) , our current data do not definitely show that the induction of endogenous aS aggregates in naive neurons is attributable to this mechanism. We speculate that exogenous aS fibrils might disrupt normal proteostatic mechanisms and endosomal/lysosomal functions resulting in inefficient degradation of endogenous aS and its subsequent aggregation. At the present time, we have no direct insight into how aS seeds might escape the endosomal membrane bound organelles. One possibility is that late endosome/lysosomes may simply be overwhelmed by the aS aggregates. This possibility is supported by the finding that chloroquine treatment results in the robust accumulation of cellular phosphorylated aggregates comprised of the exogenous aS indicting damage to endosome/lysosomal Fig. 9 Biochemical studies of endogenous aS aggregation induced by exogenous aS fibrils. Primary neuronal-glial cultures were cultured for 6 days and untreated (À) or treated (+) with 21-140 human aS fibrils (20 lg/mL) for 10 days. (a) The cultures were washed with phosphatebuffered saline and fractionated with CSK buffer as described in 'Material and Methods' to generate Triton-soluble (S) fractions and Triton-insoluble (P) fractions. The insoluble fractions were sonicated with a hand probe for 30 s to try to breakdown aggregates. Cells lysates were resolved onto 13%-polyacrylamide gels and analyzed by immunoblotting with antibody D37A6 that specifically reacts with murine aS, or antibodies Syn 204 that specifically reactions with human aS and pSer129 aS antibodies 81A, EP1536Y, or MJF-R13 (8-8). (b) The samples were further treated with 4 M urea/2% SDS for 30 min to try to break protein aggregates. The mobilities of the molecular mass markers are shown on the right. The asterisk (*) indicates a major breakdown product of exogenous aS that forms when associated with cells.
compartments resulting in leakage of the imported exogenous aS to the cytoplasm. Internalization and degradation of exogenous aS fibrils is associated with the generation of specific aS carboxy-terminal truncated fragments. Similar fragments are characteristic of aS pathological inclusions observed in human brains and transgenic mouse models (Li et al. 2005; Liu et al. 2005) . Such findings are consistent with endogenous aS aggregates overwhelming lysosomal function and locally acting as a nidus for cytoplasmic aS aggregate formation. Exogenous aS aggregates that enter cells by endocytosis may also lead to lysosome impairment and inhibition of endocytosis over time, thus increasing the time that endogenous aS interacts with the plasma membrane and allowing for direct permeabilization into the cytosol since aS can perturb membrane stability and structure (Volles et al. 2001; Auluck et al. 2010) . Alternatively, accumulation of exogenous aS fibrils in late endosomal/ lysosomal compartments could also lead to reduced degradation of normally occurring misfolded endogenous aS species that consequently coalesce to form cytosolic inclusions without direct interaction with exogenous aS.
Our current data also demonstrate that the manner in which these experiments are conducted can easily lead to a falsepositive result in which the results appear to show induction of aS inclusion pathology. First, the rapid and fairly stable attachment of exogenous fibrils to the neuronal-glial cultures essentially 'paints' the cells with the exogenous aS; unless care is taken to distinguish the exogenous fibrils from endogenous aS, this will give the impression of robust inclusion pathology. Further, as we show under conditions of chemical disruption of lysosomal degradation, exogenous aS fibrils can be internalized and phosphorylated at serine 129. Thus, these exogenous aS aggregates acquire a marker that is commonly used to track aS inclusion pathology and are present inside cells. Although variables such as the method of preparing the aS seeds may contribute to differences in the reported efficiency of seeding by different groups, our method of fibril preparation results in very efficient seeding in primary neuronal-glial cultures over-expressing aS (Sacino et al. 2013b) ; thus, we do not think that strain-like differences in aS seeds readily explain the differences in efficiency that we observed in non-aS over-expressing primary cultures.
Our studies also showed that both neurons and glial cells in our primary cultures were able to endocytose aS fibrils. It has also been demonstrated that other cell types including macrophages are able to endocytose and degrade exogenous aS (Lee et al. 2008b) . These findings indicate that this process by cells that do not normally express aS such as astrocytes constitute a biological barrier against interneuronal transmission of aS inclusion pathology if indeed secretion of aS amyloid seeds is required.
The process of intracellular aS aggregate formation and spread of aS inclusion pathology involves multiple complex mechanisms that are not mutually exclusive. Indeed, endocytosis and degradation of aS fibrils by cells that do not endogenously express aS likely constitutes an important biological barrier against intercellular transmission requiring secretion followed by internalization of aS amyloid seeds. However, under certain conditions, this mechanism can be overwhelmed or not sufficiently efficient to prevent pathological transmission. Paradoxically, this naturally protective mechanism can also be involved in importing aS amyloid seeds in neurons and when not completely effective, may contribute to the transmission of inclusion pathology. Further studies will be needed to better assess the relative contributions of these various cellular processes in mitigating and contributing to the spread of disease driven by aberrant aS aggregation.
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